Isosilychristin
Isosilychristin is a P-glycoprotein inhibitor with an IC50 of 25.9 μM. Isosilychristin downregulates the expression of transmembrane efflux pumps, exerts intracellular antioxidant effects, and inhibits NO production in macrophages. Isosilychristin regulates cell cycle progression, and exerts weak antiproliferative and colony formation inhibitory effects in prostate cancer cells. Isosilychristin reduces bacterial intercellular communication and reverses the drug resistance of Staphylococcus aureus. Isosilychristin can be used in studies related to prostate cancer, inflammation and bacterial infections.
For research use only. We do not sell to patients.
- CAS No.: 77182-66-2
- Formula: C25H22O10
- Molecular Weight:482.44
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Huh-7 | IC50 |
130 μM
Compound: 11
|
Cytotoxicity against human Huh7.5.1 cells after 72 hrs
Cytotoxicity against human Huh7.5.1 cells after 72 hrs
|
[PMID: 23673225] |
In Vitro
Isosilychristin (10-30 μM; 72 h co-incubation with Doxorubicin (HY-15142A)) exhibits only mild toxicity to HOC and HOC/ADR cells when used alone, and only weakly sensitizes HOC/ADR cells to doxorubicin at a concentration of 20 μM[1].
Isosilychristin (10 μM; 48 h) downregulates ABCB1 gene expression by 20% in HOC/ADR human ovarian cancer cells, while altering the expression of several other ABC transporter genes[1].
Isosilychristin (90 μM; 10 days) exerts only a slight inhibitory effect on colony formation of human prostate cancer PC3 cells (inhibition rate: 19.9%)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:doxorubicin-resistant (HOC/ADR) human ovarian carcinoma cells
-
Concentration:10 μM
-
Incubation Time:48 h
-
Result:Downregulated the expression of the ABCB1 (P-gp) gene by 20% in HOC/ADR cells.
Downregulated ABCA2, ABCB9, ABCC10, and ABCF1 genes.
Upregulated ABCD1, ABCD4, ABCE1, ABCF2, and ABCG4 genes.
Did not affect the expression of the ABCC2 (BCRP) gene.
-
Cell Line:human prostate carcinoma PC3 cells
-
Concentration:90 μM
-
Incubation Time:10 days (treated every 48 h)
-
Result:Inhibited PC3 cell colony formation by 19.9%.
-
Cell Line:human prostate carcinoma PC3 cells, human androgen-dependent prostate carcinoma LNCaP cells
-
Concentration:60, 90 μM
-
Incubation Time:72 h
-
Result:Elevated PC3 G2/M population to 17.45% and decreased G1 population to 51.77% with unmodified S phase at 60 μM over 72 h, while 90 μM brought no cell cycle variation to PC3 cells.
Elevated LNCaP G1 population and reduced S population without G2/M fluctuation under both concentrations; G1 reached 70.23% and S dropped to 19.91% at 60 μM, and G1 rose to 71.81% with S declining to 18.48% at 90 μM.
-
Cell Line:human prostate carcinoma PC3 cells
-
Concentration:90 μM
-
Incubation Time:72 h
-
Result:Did not cause significant changes in the expression levels of cyclins (D1, D3, E, A, B1), CDKs (2, 4, Cdc2), CDKIs (p21, p27), Skp2, phosphorylated Chk2 (Thr68), total Chk2, or Cdc25 phosphatases (A, B, C) relative to control.
- RNA extraction experimental
- Flow cytometric DNA-content cell-cycle staining
- BrdU Incorporation Assay
- Protocol for Cell Cycle
- Soft Agar Colony Formation Assay
- Research Protocol for Inflammation-related Diseases
- Colony Formation (Clonogenic) Assay
- Cell Viability Determination by MTT Colorimetric Assay
Chemical Information
-
CAS No. 77182-66-2
-
Molecular Weight 482.44
-
Formula C25H22O10
-
SMILES
OC[C@@H]1C2=C([C@H]3OC4=CC(O)=CC(O)=C4C([C@@H]3O)=O)C=CC(O)=C2O[C@H]1C5=CC(OC)=C(C=C5)O
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Viktorová J, et al. Antioxidant, Anti-Inflammatory, and Multidrug Resistance Modulation Activity of Silychristin Derivatives. Antioxidants (Basel, Switzerland). 2019 Aug 14;8(8):303. [Content Brief]
[2]. Deep G, et al. Identifying the differential effects of silymarin constituents on cell growth and cell cycle regulatory molecules in human prostate cancer cells. International journal of cancer. 2008 Jul 01;123(1):41-50. [Content Brief]
[3]. Holasová K, et al. Flavonolignans from silymarin modulate antibiotic resistance and virulence in Staphylococcus aureus. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2022 May;149:112806. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)